Analyst Ratings for Accretive Health (AH)
AH Rating Summary
AH Price Target Summary
- Highest: $21.00 (Baird)
- Lowest: $8.00 (Piper Jaffray)
- Average: $16.00
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$16.00 (+44.3%)
Avg. $ Target:
$16.00 (+44.3%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2013 | Dougherty & Co | Downgrade | Neutral (Buy) |
N/A (N/A) |
12.11 | 11.09 | -8.42% | Details |
| 1/16/2013 | Raymond James | New Coverage | Strong Buy (N/A) |
16.00 (N/A) |
12.47 | 11.09 | -11.07% | Details |
| 5/1/2012 | UBS » Updated 9/13/2012 |
Downgrade | Neutral (N/A) |
13.00 (12.00) |
10.06 | 11.09 | 10.24% | Details |
| 4/3/2012 | Goldman Sachs | Downgrade | Neutral (N/A) |
21.00 (N/A) |
20.00 | 11.09 | -44.55% | Details |
| 3/30/2012 | Baird | Downgrade | Neutral (N/A) |
21.00 (N/A) |
19.60 | 11.09 | -43.42% | Details |
| 11/30/2011 | Oppenheimer » Updated 7/31/2012 |
Upgrade | Outperform (N/A) |
17.00 (N/A) |
21.10 | 11.09 | -47.44% | Details |
| 11/22/2011 | Cowen | New Coverage | Neutral (N/A) |
N/A (N/A) |
23.69 | 11.09 | -53.19% | Details |
| 10/24/2011 | Piper Jaffray » Updated 4/30/2012 |
New Coverage | Underweight (N/A) |
8.00 (N/A) |
22.66 | 11.09 | -51.06% | Details |
| 4/13/2011 | Credit Suisse | New Coverage | Outperform (N/A) |
N/A (N/A) |
26.75 | 11.09 | -58.54% | Details |
| 1/21/2011 | Morgan Keegan | New Coverage | Market Perform (N/A) |
N/A (N/A) |
18.00 | 11.09 | -38.39% | Details |
| 11/12/2010 | Brean Capital | Upgrade | Buy (N/A) |
N/A (N/A) |
9.00 | 11.09 | 23.22% | Details |
